NCT06780085 2026-03-23
MK-3475-01H
Merck Sharp & Dohme LLC
Phase 2 Recruiting
Clinical Trials
18 trialsNCT05986318 2026-03-09
RESPIRE-ILD
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Phase 2 Recruiting
NCT07378761 2026-01-30
CHILURSO
University Hospital, Montpellier
Phase 2 Not yet recruiting
NCT01059786 2025-06-12
Randomized Phase II Trial of Rituximab With Either Pentostatin or Bendamustine for Multiply Relapsed or Refractory Hairy Cell Leukemia
National Institutes of Health Clinical Center (CC)
Phase 2 Active not recruiting
NCT05660421 2024-10-31
Itacitinib for the Treatment Steroid Refractory Immune Related Adverse Events Arising From Immune Checkpoint Inhibitors
Vanderbilt-Ingram Cancer Center
Phase 2 Withdrawn
NCT03003520 2023-05-22
A Study of Durvalumab in Combination With R-CHOP or Lenalidomide Plus R-CHOP in Previously Untreated High-Risk Diffuse Large B-Cell Lymphoma
Celgene
Phase 2 Completed
NCT02490878 2023-03-23
Corticosteroids + Bevacizumab vs. Corticosteroids + Placebo (BEST) for Radionecrosis After Radiosurgery for Brain Metastases
Alliance for Clinical Trials in Oncology
Phase 2 Terminated
NCT04810156 2022-12-14
I-HEP
Herlev Hospital
Phase 2 Unknown
NCT03050866 2021-08-20
CABA-V7
Erasmus Medical Center
Phase 2 Unknown
NCT01497496 2021-04-27
Ofatumumab/Methylprednisolone and Ofatumumab/Lenalidomide for Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Completed
NCT02410382 2019-05-14
Dexamethasone for Treatment of Radiation-related Fatigue in Patients Receiving RT for Head-neck and Lung Cancer
University of Arizona
Phase 2 Terminated
NCT01621880 2019-01-09
BRAIN
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2 Completed
NCT01074437 2018-10-04
Corticosteroids With Placebo Versus Corticosteroids With Propranolol Treatment of Infantile Hemangiomas (IH)
Seattle Children's Hospital
Phase 2 Terminated
NCT01393730 2018-03-15
Abiraterone Acetate Combined With Dutasteride for Metastatic Castrate Resistant Prostate Cancer
Dana-Farber Cancer Institute
Phase 2 Completed
NCT01414205 2017-04-17
A Study Comparing Obinutuzumab (RO5072759; GA101) 1000 Milligram (mg) Versus 2000 mg in Participants With Previously Untreated Chronic Lymphocytic Leukemia (CLL) (GAGE)
Genentech, Inc.
Phase 2 Completed
NCT01072045 2014-12-02
Comparative Study of the Use of Beta Blocker and Oral Corticosteroid in the Treatment of Infantile Hemangioma
University of Sao Paulo
Phase 2 Completed
NCT00006371 2012-09-27
A Phase II Trial of Early Medical Adrenalectomy for "D0.5" Prostate Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Terminated
NCT00946374 2009-07-27
HD-MCL2003
Heidelberg University
Phase 2 Unknown